Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization

被引：0

作者：

Tauser, Roxana-Georgiana ^{[1
]}

Zugun-Eloae, Florin ^{[2
]}

Jitaru, Daniela ^{[3
]}

Carasevici, Eugen ^{[2
]}

机构：

[1] Gr T Popa Univ Med & Pharm Iasi, Dept Med Chem, Sch Pharm, Iasi 700115, Romania

[2] Gr T Popa Univ Med & Pharm Iasi, Sch Med, Dept Immunol, Iasi 700115, Romania

[3] St Spiridon Univ Emmergency Hosp Iasi, Iasi, Romania

来源：

REVISTA ROMANA DE MEDICINA DE LABORATOR | 2009年 / 16卷 / 03期

关键词：

pharmacogenetics; bevacizumab; hypoxia inducible factor; cancer; CIRCULATING ENDOTHELIAL-CELLS; METASTATIC COLORECTAL-CANCER; BREAST-CANCER; POLYMORPHISMS; ANGIOGENESIS; CHALLENGES; FLUOROURACIL; CHEMOTHERAPY; LEUCOVORIN; GENE;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Pharmacogenetics of innovative angiogenic-targeted monoclonal antibody therapy, yet in its infancy, will be crucial in treatment individualization according to the genetic profile of each patient and molecular features of tumors. Bevacizumab (Avastin) specifically targets the key promotor of angiogenesis - vascular endothelial growth factor (VEGF), whose transcription is critically regulated by hypoxia-inducible factor HIF-1 alpha. The present paper points out the clinical relevance of HIF-1 alpha common genetic polymorphisms to the inter-individual variability in response to anti-VEGF-targeted monoclonal antibody therapeutic regimens, with special reference to colorectal cancer.

引用

页码：7 / 12

页数：6

共 50 条

[11] Molecular modeling of the hypoxia-inducible factor-1 (HIF-1)
G. Michel
E. Minet
I. Ernest
F. Durant
J. Remacle
C. Michiels
Theoretical Chemistry Accounts, 1999, 101 : 51 - 56
[12] Hypoxia-Inducible Factor-1 (HIF-1)-Active Cells as a Target for Cancer Therapy
Kizaka-Kondoh, Shinae
Kuchimaru, Takahiro
Kadonosono, Tetsuya
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 (04) : 440 - 445
[13] Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
Falchook, Gerald S.
Wheler, Jennifer J.
Naing, Aung
Jackson, Edward F.
Janku, Filip
Hong, David
Ng, Chaan S.
Tannir, Nizar M.
Lawhorn, Kristie N.
Huang, Mei
Angelo, Laura S.
Vishwamitra, Deeksha
Hess, Kenneth
Howard, Adrienne N.
Parkhurst, Kristin L.
Amin, Hesham M.
Kurzrock, Razelle
ONCOTARGET, 2014, 5 (21) : 10280 - 10292
[14] Casein kinase 1 regulates human hypoxia-inducible factor HIF-1
Kalousi, Alkmini
Mylonis, Ilias
Politou, Anastasia S.
Chachami, Georgia
Paraskeva, Efrosyni
Simos, George
JOURNAL OF CELL SCIENCE, 2010, 123 (17) : 2976 - 2986
[15] ELUCIDATING THE MECHANISM OF HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) REGULATION IN KIDNEY
Yamaguchi, Junna
Tanaka, Tetsuhiro
Eto, Nobuaki
Nangaku, Masaomi
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
[16] The function of hypoxia-inducible factor 1 (HIF-1) is impaired in senescent mice
Frenkel-Denkberg, G
Gershon, D
Levy, AP
FEBS LETTERS, 1999, 462 (03) : 341 - 344
[17] Hypoxia-inducible factor-1 (HIF-1) is protective for experimental colitis
Karhausen, JA
Furuta, GT
Haase, VH
Jaenisch, R
Johnson, RS
Colgan, SP
GASTROENTEROLOGY, 2002, 122 (04) : A6 - A6
[18] Total synthesis of verucopeptin, an inhibitor of hypoxia-inducible factor 1 (HIF-1)
Takahashi, Nobuaki
Hayashi, Hideaki
Poznaks, Viktors
Kakeya, Hideaki
CHEMICAL COMMUNICATIONS, 2019, 55 (79) : 11956 - 11959
[19] Expression of hypoxia-inducible factor-1α (HIF-1α) in pituitary tumours
Vidal, S
Horvath, E
Kovacs, K
Kuroki, T
Lloyd, RV
Scheithauer, BW
HISTOLOGY AND HISTOPATHOLOGY, 2003, 18 (03) : 679 - 686
[20] Roles of the HIF-1 hypoxia-inducible factor during hypoxia response in Caenorhabditis elegans
Shen, C
Nettleton, D
Jiang, M
Kim, SK
Powell-Coffman, JA
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (21) : 20580 - 20588

← 1 2 3 4 5 →